Toxoplasmosis infection in newborn: A systematic review and meta-analysis

Abstract

Background: Toxoplasmosis is a disease caused by Toxoplasma gondii, and one-third of the world's population has T. gondii antibodies. Due to this issue, the aim of this study was to assess the mean prevalence and odds ratios of T. gondii infection and epidemiological features of neonatal infection worldwide. Materials and Methods: We performed a meta-analysis and systematic review of published studies reporting T. gondii infection using the PubMed, MEDLINE, Web of Science, EMBASE, and Scopus electronic databases through January 1999 to December 2020, regarding diagnostic tests, and prevalence data of infection among the newborn population. The pooled prevalence of T. gondii with a 95% confidence interval (CI) was calculated using the random-effects models. Results: A total of thirty eligible articles were included. The estimated global prevalence rate was 44% (95% CI: 29%–0.58%); the highest prevalence rate was in America 47% (95% CI: 30%–64%), followed by Europe 41% (95% CI: 26%–57%) and Asia 33% (95% CI: 4%–61%). In this study, despite our careful analysis of possible modifiers, the heterogeneity was significant ( P = 0.000). The publication bias was not significant based on the results of Egger's ( P = 0.918) and Begg's tests ( P = 0.230). Conclusion: Based on the results of this study, T. gondii infection can be a serious concern in newborns around the world. Therefore, further research is needed to provide better strategies to screen and diagnose T. gondii infection in neonates and determine the risk factors associated with the prevalence of infection in neonates worldwide.

Anti-Toxoplasma gondii screening of MMV pandemic response box and evaluation of RWJ-67657 efficacy in chronically infected mice

“…With approximately 35% of the world's population affected during their lifetime, toxoplasmosis stands as the most prevalent parasitic zoonotic disease globally. In humans, toxoplasmosis can lead to severe complications, particularly in fetuses, new-borns and immunocompromised individuals (Akbari et al ., 2022).…”